Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in adults with immune thrombocytopenia after failure of first-line treatment
2025-522070-36-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of rilzabrutinib in immune thrombocytopenia (ITP), sponsored by Sanofi. Primary endpoint: Durable platelet response. Planned start Dec 2025; status: authorised.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2025-522070-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522070-36-00.